Enhertu, known generically as trastuzumab deruxtecan, represents a significant advancement in the treatment landscape.
What is Enhertu? A Targeted Therapy for Advanced Cancers
Enhertu, known generically as trastuzumab deruxtecan, represents a significant advancement in the treatment landscape for certain types of advanced cancers. It is a prescription medication classified as an antibody-drug conjugate (ADC), designed to precisely target and deliver chemotherapy directly to cancer cells while minimizing impact on healthy cells.
Understanding Enhertu: Mechanism of Action
Enhertu is composed of three main parts: an antibody, a linker, and a chemotherapy drug. The antibody component is trastuzumab, which specifically targets the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a protein found on the surface of some cancer cells, and its overexpression can drive cancer growth. The linker attaches this antibody to a potent chemotherapy drug, deruxtecan (a topoisomerase I inhibitor).
When Enhertu is administered, the trastuzumab antibody seeks out and binds to HER2 proteins on the surface of cancer cells. Once attached, the entire complex is internalized by the cancer cell. Inside the cell, the linker breaks down, releasing the chemotherapy drug deruxtecan. This targeted delivery allows the chemotherapy to concentrate its effects within the cancer cells, aiming to destroy them while potentially reducing systemic side effects often associated with traditional chemotherapy.
Approved Uses of Enhertu
Enhertu has received approval for treating specific types of cancers, primarily those that are HER2-positive or HER2-low, and often in advanced or metastatic stages where other treatments have been tried.
Enhertu for Breast Cancer
Enhertu is approved for treating adult patients with:
- HER2-positive metastatic breast cancer: For those who have received a prior anti-HER2 based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and developed disease recurrence during or within six months of completing therapy.
- HER2-low metastatic breast cancer: For those who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
Enhertu for Gastric Cancer
Enhertu is also indicated for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Enhertu for Lung Cancer
For lung cancer, Enhertu is approved for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
How Enhertu is Administered
Enhertu is administered as an intravenous (IV) infusion, meaning it is given directly into a vein. The treatment is typically given in cycles, with the dosage and frequency determined by a healthcare professional based on the patient's condition, weight, and response to therapy. It is crucial that Enhertu is administered by healthcare professionals in a clinical setting equipped to manage potential side effects.
Important Safety Information and Considerations
As a potent cancer therapy, Enhertu carries important safety considerations. Patients undergoing treatment with Enhertu must be closely monitored by their healthcare team for potential side effects. Some serious potential side effects include interstitial lung disease (ILD) / pneumonitis, neutropenia (low white blood cell count), and cardiac toxicity. Other common side effects may include nausea, fatigue, hair loss, and vomiting.
It is paramount for patients to have open and thorough discussions with their doctor about all potential risks and benefits of Enhertu. The decision to use Enhertu is highly individualized and depends on the specific type and stage of cancer, previous treatments, and overall patient health. Enhertu is not suitable for everyone, and a qualified healthcare provider can determine if it is an appropriate treatment option.
Conclusion
Enhertu represents a valuable treatment option for specific populations of patients with advanced HER2-positive or HER2-low breast, gastric, and HER2-mutant non-small cell lung cancers. Its targeted mechanism offers a precision approach to fighting cancer. However, like all powerful medications, its use requires careful consideration, expert medical supervision, and continuous monitoring to ensure patient safety and optimize treatment outcomes.